Meta Platforms heads into its May 27 earnings announcement having absorbed a wave of post-Q1 analyst target cuts — and with short sellers now building positions at the fastest pace in weeks.
The most notable shift this week is on the short side. Short interest climbed roughly 9.5% over the past five trading days to 1.3% of the free float — a level still modest in absolute terms, but the pace of accumulation is striking. From early April through early May, the position held steady around 26 million shares. It then jumped by roughly 2.6 million shares in a single session over the May 8-11 weekend, reaching 29.1 million. Over a rolling month, the position has grown nearly 20%. Days to cover remain shallow at 0.56, so this is a fresh accumulation rather than a structural short thesis — but shorts are clearly more active than they have been all year.
Borrow conditions give no particular support to squeeze hopes. Availability remains loose: cost to borrow is a negligible 0.37%, essentially at general collateral rates, and the borrow pool appears far from stressed. The week did see a brief spike in cost to borrow on May 8 (up to 0.48%), but it has since eased back. The put/call ratio tells the opposite story. At 0.47, the PCR has dropped to its lowest level in the past 52 weeks — more than 2.5 standard deviations below its 20-day average of 0.50. Options traders are not hedging into this print; they are reaching for upside. The divergence between a rebuilding short interest and an unusually call-heavy options market sets up a genuine tension in how professional money is positioned.
The analyst community responded to Q1 results in near-uniform fashion: nearly every major firm trimmed its price target, even those maintaining constructive ratings. JP Morgan's Doug Anmuth — the most consequential move — dropped from Overweight to Neutral with a cut from $825 to $725, citing the gap between execution and near-term valuation. Mizuho, Barclays, Bernstein, TD Cowen, Piper Sandler, and UBS all lowered targets while holding Buy or Outperform ratings, clustering new targets in the $800–$865 range. The consensus mean lands at $827, implying roughly 37% upside from the current $603 close. That is a wide gap, but the direction of the revisions is clear — the Street still believes in the story, but the earnings reaction knocked some premium out. The trailing PE has compressed about two points over 30 days to 18x, while EV/EBITDA has eased slightly. Revenue grew 33% year-on-year in the most recent quarter, gross margins held above 81%, and EBITDA margins exceeded 51%. The factor scores reinforce a growth-versus-value tension: EPS momentum ranks in the 81st percentile over 30 days and 75th over 90 days, while the EV/EBIT factor scores in the 36th percentile — expensive by historical measures, excellent by fundamental trend.
The reaction to the most recent Q1 report on April 29 is worth noting. The stock fell 8.9% the following day and was still down 8.7% five days later. That is the full earnings history available in the data, and it captures a market that sold the print despite broadly strong numbers — the kind of reaction that can recalibrate expectations ahead of the next report. With the May 27 announcement now less than two weeks away, the RSI at 41 flags the stock as oversold territory relative to its recent range; META is down 4.3% over the past month and off 9.3% year-to-date from a starting point well above $660.
The short score at 29.3 — while ticking up daily — remains well below distress levels. Availability in the lending market is wide open, borrow is cheap, and the float is too large for a squeeze scenario to develop quickly. What to watch into May 27: whether the call-heavy options positioning holds as the print approaches, and whether short interest continues building at the current pace or plateaus — the two together will say most of what there is to know about how money is leaning on the next catalyst.
See the live data behind this article on ORTEX.
Open META on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
